Maple The incretin signaling pathway represents one of the most actively studied axes in metabolic research. GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors regulate insulin secretion, gastric motility, hepatic glucose output, and energy expenditure through distinct but overlapping mechanisms.
Maple Research Labs supplies research-grade incretin pathway peptides to Canadian laboratories, universities, and documented research buyers. Every compound ships with a batch-specific Certificate of Analysis verified by independent third-party testing.
All compounds listed below are sold exclusively for in-vitro and preclinical research applications. For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Understanding the Incretin Receptor System
Three receptor subtypes define the incretin and related metabolic signaling pathways studied in current peptide research:
GLP-1 Receptor (GLP-1R). Expressed in pancreatic beta cells, the central nervous system, and gastrointestinal tract. Activation stimulates glucose-dependent insulin secretion, delays gastric emptying, and modulates appetite-related signaling in preclinical models. GLP-1R is the primary target of single-agonist compounds such as semaglutide analogues.
GIP Receptor (GIPR). Expressed in pancreatic islets, adipose tissue, and bone. GIP potentiates insulin secretion in a glucose-dependent manner and appears to modulate lipid metabolism in adipocytes. Dual GIP/GLP-1 agonism is the mechanism studied in tirzepatide-class compounds.
Glucagon Receptor (GCGR). Expressed primarily in the liver. Glucagon receptor activation increases hepatic glucose output and stimulates energy expenditure through thermogenic pathways. When combined with GLP-1R and GIPR agonism, the insulinotropic effects of the latter two receptors counterbalance the glycemic impact of GCGR activation while preserving increased metabolic rate. This triple-agonist approach is the basis of retatrutide-class research.
The progression from single-agonist to dual-agonist to triple-agonist compounds reflects the trajectory of incretin pathway research: each additional receptor target introduces new signaling interactions that are actively being characterized in preclinical and clinical trial settings.
Research Compounds in This Category
Retatrutide (LY3437943) – Triple GLP-1/GIP/Glucagon Receptor Agonist
Retatrutide is a synthetic 39-amino acid peptide engineered to simultaneously activate GLP-1R, GIPR, and GCGR. It represents the first triple incretin receptor agonist to advance through large-scale clinical trials.
Receptor binding profile: Relative to endogenous ligands, retatrutide demonstrates approximately 8.9-fold greater potency at GIPR, 0.4-fold potency at GLP-1R, and 0.3-fold potency at GCGR. This imbalanced agonism profile is a key area of investigation in understanding how receptor selectivity ratios influence downstream metabolic effects.
Research context: Phase 2 trial data (Jastreboff et al., published in The New England Journal of Medicine) examined dose-dependent pharmacodynamic responses across multiple endpoints. Phase 3 investigation is ongoing under Eli Lilly. Preclinical models have also characterized retatrutide’s effects on hepatic lipid parameters, with Phase 2a data published in Nature Medicine providing early pharmacological context for the triple-agonist mechanism.
CAS Number: 2381089-83-2
Molecular Formula: C207H312N48O63S
Available at Maple Research Labs: View Retatrutide Product Page
Tirzepatide (LY3298176) – Dual GIP/GLP-1 Receptor Agonist
Tirzepatide is a 39-amino acid synthetic peptide with a C20 fatty di-acid moiety that extends its circulating half-life through enhanced albumin binding. Its structure is based on the native GIP sequence, modified to achieve dual receptor engagement.
Mechanism distinction: Unlike balanced dual agonists, tirzepatide is an imbalanced and biased agonist. It binds GIPR with affinity equivalent to native GIP but engages GLP-1R with approximately 5-fold lower affinity than native GLP-1. At GLP-1R, tirzepatide demonstrates biased signaling, favoring cAMP generation over beta-arrestin recruitment. This biased agonism results in reduced GLP-1R internalization compared to native GLP-1, a pharmacological property under active investigation for its functional significance (Willard et al., JCI Insight, 2020).
Research context: Tirzepatide received FDA approval under the brand name Mounjaro (2022) and Zepbound (2023). Preclinical research continues to explore its effects on insulin sensitivity, beta-cell function, and neurological signaling pathways.
CAS Number: 2023788-19-2
Molecular Formula: C225H348N48O68
Available at Maple Research Labs: View Tirzepatide Product Page
Semaglutide Analogues – Selective GLP-1 Receptor Agonist
Semaglutide is a DPP-4-resistant GLP-1 receptor agonist engineered through strategic amino acid substitutions and the addition of a C18 fatty diacid side chain. These modifications extend its circulating half-life to approximately 160 hours, a pharmacokinetic property that has been extensively characterized in both preclinical and clinical research settings.
Mechanism: Semaglutide binds and activates GLP-1R, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release, and modulating gastric motility and central appetite signaling. As a selective single-agonist, semaglutide serves as the baseline comparator in research examining whether dual or triple agonism confers additional metabolic effects beyond GLP-1R activation alone.
Research context: With thousands of indexed preclinical and clinical publications, semaglutide is the most extensively characterized GLP-1R agonist. Current research extends beyond metabolic applications into neurological models, examining effects on neurogenesis, oxidative stress, and neuroinflammation.
CAS Number: 910463-68-2
Molecular Formula: C187H291N45O59
Available at Maple Research Labs: View Semaglutide Product Page
Why Researchers Source Incretin Pathway Peptides from Maple Research Labs
Third-party COA verification on every batch. Each compound ships with an independent Certificate of Analysis confirming identity, purity (HPLC), and absence of contaminants. COA documents are linked directly on every product page and available for download before purchase. This is not a marketing claim. It is the operational standard.
Canadian supply chain. Maple Research Labs ships from within Canada. For Canadian research institutions, this eliminates customs delays, cross-border documentation, and the compliance ambiguity of importing research compounds from US or offshore suppliers.
Same-day processing. Orders placed before the daily cutoff ship the same business day. Consistent supply timelines matter for research protocols with time-sensitive experimental windows.
Research-only positioning. Every product page includes mechanism of action summaries, CAS numbers, molecular formulas, storage specifications, and research-use disclaimers. We do not publish dosing protocols, administration guidance, or therapeutic claims.
Single vs. Dual vs. Triple Agonism: A Research Framework
The incretin pathway research landscape has shifted from single-target to multi-target peptide design. Understanding the receptor engagement profile of each compound class is essential for selecting the appropriate research tool.
| Feature | Single Agonist (Semaglutide) | Dual Agonist (Tirzepatide) | Triple Agonist (Retatrutide) |
|---|---|---|---|
| Receptor targets | GLP-1R only | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| GLP-1R engagement | High potency, balanced signaling | Reduced potency, biased toward cAMP | Moderate potency (0.4x endogenous) |
| GIPR engagement | None | Equivalent to native GIP | Enhanced (8.9x endogenous) |
| GCGR engagement | None | None | Moderate (0.3x endogenous) |
| Key research question | Baseline GLP-1R pharmacology | Does GIP co-agonism enhance metabolic outcomes? | Does glucagon receptor addition increase energy expenditure without glycemic disruption? |
| Literature volume | Highest (thousands of indexed studies) | Moderate (growing rapidly post-approval) | Early stage (Phase 2/3 data emerging) |
This comparison is intended as a research selection framework, not a therapeutic recommendation. All compounds are supplied for preclinical and in-vitro investigation only.
Frequently Asked Questions
What is the incretin pathway and why is it significant in peptide research?
The incretin pathway refers to the hormonal signaling system involving GLP-1 and GIP, peptides released from the gut in response to nutrient intake. These hormones potentiate glucose-dependent insulin secretion from pancreatic beta cells, a mechanism called the “incretin effect.” In research settings, the incretin pathway is significant because it represents a well-characterized signaling axis with multiple targetable receptors (GLP-1R, GIPR, GCGR), enabling the study of single, dual, and triple receptor agonism in preclinical metabolic models.
What is the difference between single, dual, and triple agonist research peptides?
Single agonists (e.g., semaglutide analogues) activate one receptor, typically GLP-1R. Dual agonists (e.g., tirzepatide) engage two receptors simultaneously, in this case GLP-1R and GIPR, with an imbalanced potency profile. Triple agonists (e.g., retatrutide) activate GLP-1R, GIPR, and GCGR. Each class represents a different experimental tool for studying how multi-receptor engagement modifies downstream metabolic signaling compared to single-target activation.
Can I purchase GLP-1 research peptides in Canada?
Yes. Maple Research Labs is a Canadian supplier of research-grade incretin pathway peptides, including retatrutide, tirzepatide, and semaglutide analogues. All compounds ship from within Canada with same-day processing and include batch-specific Certificates of Analysis. These peptides are sold exclusively for research purposes and are not approved for human therapeutic use.
What purity standards do Maple Research Labs peptides meet?
All incretin pathway peptides are verified at 99%+ purity via HPLC analysis conducted by independent third-party laboratories. Each batch ships with a downloadable Certificate of Analysis confirming identity, purity percentage, and the absence of relevant contaminants. COA documents are publicly linked on each product page.
How should research peptides be stored?
Lyophilized peptides should be stored at -20°C in a desiccated environment, protected from light. Reconstituted peptides should be stored at 2-8°C (refrigerated) and used within the timeframe specified on the product page. Avoid repeated freeze-thaw cycles, as these can degrade peptide integrity and compromise experimental reproducibility.
Are these peptides approved for human use?
No. All peptides sold by Maple Research Labs are designated for in-vitro and preclinical research use only. They are not approved by Health Canada or any regulatory agency for human diagnostic, therapeutic, or consumption purposes. Researchers are responsible for compliance with applicable institutional and jurisdictional regulations governing research compound procurement and use.
What documentation ships with each order?
Every order includes a batch-specific Certificate of Analysis, product specification sheet, and storage instructions. For institutional or bulk research orders, Maple Research Labs can provide additional documentation to support procurement compliance requirements.
Related Research Resources
Explore more research peptide information from Maple Research Labs:
BPC-157 Research Peptide | TB-500 (Thymosin Beta-4) Research Peptide | How to Read a Certificate of Analysis | Third-Party Peptide Purity Verification | BPC-157 vs TB-500 Research Comparison
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.